Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 2
1950 2
1951 1
1953 1
1955 1
1962 1
1971 1
1972 2
1973 1
1979 1
1982 1
1986 1
1988 1
1990 1
1998 1
2005 1
2006 1
2008 2
2009 2
2010 2
2011 3
2012 1
2013 3
2014 2
2015 2
2016 2
2017 4
2018 5
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Results by year
Filters applied: . Clear all
Page 1
Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Among authors: kline cl. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Oncotarget. 2016. PMID: 27602582 Free PMC article. Review.
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Wagner J, et al. Among authors: kline cl. J Clin Invest. 2018 Jun 1;128(6):2325-2338. doi: 10.1172/JCI96711. Epub 2018 Apr 30. J Clin Invest. 2018. PMID: 29533922 Free PMC article.
Par-4 as a potential target for cancer therapy.
Irby RB, Kline CL. Irby RB, et al. Among authors: kline cl. Expert Opin Ther Targets. 2013 Jan;17(1):77-87. doi: 10.1517/14728222.2013.731047. Epub 2012 Oct 15. Expert Opin Ther Targets. 2013. PMID: 23062118 Review.
Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Kline CLB, et al. Neoplasia. 2018 Jan;20(1):80-91. doi: 10.1016/j.neo.2017.10.002. Epub 2017 Dec 5. Neoplasia. 2018. PMID: 29216597 Free PMC article.
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Prabhu VV, et al. Among authors: kline clb. Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17. Clin Cancer Res. 2019. PMID: 30559168 Free PMC article.
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS. Prabhu VV, et al. Among authors: kline clb. Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19. Cell Cycle. 2018. PMID: 29157092 Free PMC article.
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Prabhu VV, et al. Among authors: kline clb. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017. PLoS One. 2017. PMID: 28767654 Free PMC article.
44 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page